195 related articles for article (PubMed ID: 34151854)
1. Revertant Phenomenon in DMD and LGMD2I and Its Therapeutic Implications: A Review of Study Under Mentorship of Terrence Partridge.
Lu QL
J Neuromuscul Dis; 2021; 8(s2):S359-S367. PubMed ID: 34151854
[TBL] [Abstract][Full Text] [Related]
2. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
3. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
[TBL] [Abstract][Full Text] [Related]
4. Efficient engraftment of pluripotent stem cell-derived myogenic progenitors in a novel immunodeficient mouse model of limb girdle muscular dystrophy 2I.
Azzag K; Ortiz-Cordero C; Oliveira NAJ; Magli A; Selvaraj S; Tungtur S; Upchurch W; Iaizzo PA; Lu QL; Perlingeiro RCR
Skelet Muscle; 2020 Apr; 10(1):10. PubMed ID: 32321586
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
6. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
7. NAD+ enhances ribitol and ribose rescue of α-dystroglycan functional glycosylation in human FKRP-mutant myotubes.
Ortiz-Cordero C; Magli A; Dhoke NR; Kuebler T; Selvaraj S; Oliveira NA; Zhou H; Sham YY; Bang AG; Perlingeiro RC
Elife; 2021 Jan; 10():. PubMed ID: 33513091
[TBL] [Abstract][Full Text] [Related]
8. Muscle and heart function restoration in a limb girdle muscular dystrophy 2I (LGMD2I) mouse model by systemic FKRP gene delivery.
Qiao C; Wang CH; Zhao C; Lu P; Awano H; Xiao B; Li J; Yuan Z; Dai Y; Martin CB; Li J; Lu Q; Xiao X
Mol Ther; 2014 Nov; 22(11):1890-9. PubMed ID: 25048216
[TBL] [Abstract][Full Text] [Related]
9. Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy.
Kendall GC; Mokhonova EI; Moran M; Sejbuk NE; Wang DW; Silva O; Wang RT; Martinez L; Lu QL; Damoiseaux R; Spencer MJ; Nelson SF; Miceli MC
Sci Transl Med; 2012 Dec; 4(164):164ra160. PubMed ID: 23241744
[TBL] [Abstract][Full Text] [Related]
10. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.
Aartsma-Rus A; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S71-7. PubMed ID: 12206800
[TBL] [Abstract][Full Text] [Related]
11. New developments in exon skipping and splice modulation therapies for neuromuscular diseases.
Touznik A; Lee JJ; Yokota T
Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745
[TBL] [Abstract][Full Text] [Related]
12. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
[TBL] [Abstract][Full Text] [Related]
13. Ribitol dose-dependently enhances matriglycan expression and improves muscle function with prolonged life span in limb girdle muscular dystrophy 2I mouse model.
Wu B; Drains M; Shah SN; Lu PJ; Leroy V; Killilee J; Rawls R; Tucker JD; Blaeser A; Lu QL
PLoS One; 2022; 17(12):e0278482. PubMed ID: 36454905
[TBL] [Abstract][Full Text] [Related]
14. Improved efficacy of FKRP AAV gene therapy by combination with ribitol treatment for LGMD2I.
Cataldi MP; Vannoy CH; Blaeser A; Tucker JD; Leroy V; Rawls R; Killilee J; Holbrook MC; Lu QL
Mol Ther; 2023 Dec; 31(12):3478-3489. PubMed ID: 37919902
[TBL] [Abstract][Full Text] [Related]
15. AAV-mediated transfer of FKRP shows therapeutic efficacy in a murine model but requires control of gene expression.
Gicquel E; Maizonnier N; Foltz SJ; Martin WJ; Bourg N; Svinartchouk F; Charton K; Beedle AM; Richard I
Hum Mol Genet; 2017 May; 26(10):1952-1965. PubMed ID: 28334834
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates.
Lim KRQ; Echigoya Y; Nagata T; Kuraoka M; Kobayashi M; Aoki Y; Partridge T; Maruyama R; Takeda S; Yokota T
Mol Ther; 2019 Jan; 27(1):76-86. PubMed ID: 30448197
[TBL] [Abstract][Full Text] [Related]
17. Exon skipping quantification by quantitative reverse-transcription polymerase chain reaction in Duchenne muscular dystrophy patients treated with the antisense oligomer eteplirsen.
Anthony K; Feng L; Arechavala-Gomeza V; Guglieri M; Straub V; Bushby K; Cirak S; Morgan J; Muntoni F
Hum Gene Ther Methods; 2012 Oct; 23(5):336-45. PubMed ID: 23075107
[TBL] [Abstract][Full Text] [Related]
18. Contributions of Japanese patients to development of antisense therapy for DMD.
Matsuo M; Takeshima Y; Nishio H
Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
[TBL] [Abstract][Full Text] [Related]
19. Autologous intramuscular transplantation of engineered satellite cells induces exosome-mediated systemic expression of Fukutin-related protein and rescues disease phenotype in a murine model of limb-girdle muscular dystrophy type 2I.
Frattini P; Villa C; De Santis F; Meregalli M; Belicchi M; Erratico S; Bella P; Raimondi MT; Lu Q; Torrente Y
Hum Mol Genet; 2017 Oct; 26(19):3682-3698. PubMed ID: 28666318
[TBL] [Abstract][Full Text] [Related]
20. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
Echigoya Y; Yokota T
Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
